EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?

Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, Benoit Dumont, Anne-Sophie Defachelles, Estelle Thebaud, Julie Tandonnet, Claudia Pasqualini, Stéphanie Proust, Natacha Entz-Werle, Isabelle Aerts, Lee A Ndounga-Diakou und 13 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Patricia Raiser und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, 94805 Villejuif, France. Hauptthemen laut MEDLINE: Topotecan, Neuroblastoma, Antibodies, Monoclonal. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TopotecanNeuroblastomaAntibodies, MonoclonalChildHumansInfantChild, PreschoolAdolescentYoung AdultAdultTemozolomideProspective StudiesDisease-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalCyclophosphamideIrinotecanImmunotherapyRecurrence

Stichwörter der Autor:innen

ChemotherapyDinutuximab betaImmunotherapyNeuroblastomaReal-world dataRelapse

Substanzen

dinutuximabTopotecanTemozolomideCyclophosphamideIrinotecanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, 94805 Villejuif, France.
  • RTOP (Recherche Translationelle en Oncologie Pediatrique), U830 INSERM, Institut Curie, PSL Research University, 75005 Paris, France; SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cance…
  • Department of Pediatric Oncology, Toulouse University Hospital, 31300 Toulouse, France.
  • Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique/Centre Léon Bérard, 69008 Lyon, France.
  • Department of Pediatric Oncology, Oscar Lambret Cancer Center, 59000 Lille, France.
  • Pediatric Immuno-Hemato-Oncology Unit, CHU Nantes, 44000 Nantes, France.

Zitieren

APA

Raiser, P., Schleiermacher, G., Gambart, M., Dumont, B., Defachelles, A. S., Thebaud, E., Tandonnet, J., Pasqualini, C., Proust, S., Entz-Werle, N., Aerts, I., Ndounga-Diakou, L. A., Petit, A., Puiseux, C., Khanfar, C., Rouger, J., Mansuy, L., Benadiba, J., Millot, F., …, & Berlanga, P. (2024). Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114001

Vancouver

Raiser P, Schleiermacher G, Gambart M, Dumont B, Defachelles AS, Thebaud E, et al. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114001

BibTeX
@article{Raiser2024,
  author = {Raiser, Patricia and Schleiermacher, Gudrun and Gambart, Marion and Dumont, Benoit and Defachelles, Anne-Sophie and Thebaud, Estelle and Tandonnet, Julie and Pasqualini, Claudia and Proust, Stéphanie and Entz-Werle, Natacha and Aerts, Isabelle and Ndounga-Diakou, Lee A and Petit, Arnaud and Puiseux, Chloe and Khanfar, Camille and Rouger, Jeremie and Mansuy, Ludovic and Benadiba, Joy and Millot, Frédéric and Pluchart, Claire and Laghouati, Salim and Geoerger, Birgit and Vassal, Gilles and Valteau-Couanet, Dominique and Berlanga, Pablo},
  title = {Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114001}
}
Kostenlos starten →